New treatment insights into pancreatic acinar cell carcinoma: case report and literature review

Front Oncol. 2023 Jul 3:13:1210064. doi: 10.3389/fonc.2023.1210064. eCollection 2023.

Abstract

Pancreatic acinar cell carcinoma (PACC) is a rare pancreatic malignancy with unique clinical, molecular, and morphologic features. The long-term survival of patients with PACC is substantially better than that of patients with ductal adenocarcinoma of the pancreas. Surgical resection is considered the first choice for treatment; however, there is no standard treatment option for patients with inoperable disease. The patient with metastatic PACC reported herein survived for more than 5 years with various treatments including chemotherapy, radiotherapy, antiangiogenic therapy and combined immunotherapy.

Keywords: antiangiogenic therapy; chemotherapy; immunotherapy; pancreatic acinar cell carcinoma; radiotherapy.

Publication types

  • Review

Grants and funding

This research was supported by Renmin Hospital of Wuhan University Cross-Innovation Talent Project (JCRCWL-2022-003).